2019
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley‐Bosco E, Galateau‐Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA A Cancer Journal For Clinicians 2019, 69: 402-429. PMID: 31283845, PMCID: PMC8192079, DOI: 10.3322/caac.21572.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalAsbestosAustraliaBiomarkers, TumorCarcinogenesisCombined Modality TherapyDiagnostic ErrorsEuropeGenetic Predisposition to DiseaseGerm-Line MutationGlobal Burden of DiseaseHumansIncidenceInhalation ExposureInternational CooperationMesotheliomaMolecular Targeted TherapyOccupational ExposurePleuraPleural NeoplasmsPneumonectomyPrognosisTumor Suppressor ProteinsUbiquitin ThiolesteraseUnited StatesConceptsNovel systemic treatmentsRole of surgeryKey pathogenic mechanismsAccuracy of diagnosisAggressive managementSystemic treatmentLocal therapyPeritoneal mesotheliomaPleural mesotheliomaMesothelioma incidenceIncidence rateTreatment outcomesProtein 1 mutationImmune responseGermline BRCA1Epidemiological studiesMortality ratePathogenic mechanismsMesotheliomaMesothelioma diagnosisUse of asbestosInadequate treatmentOlder individualsOlder peopleEarly detection
2018
Predicting breast cancer therapeutic response
Garrido-Castro AC, Winer EP. Predicting breast cancer therapeutic response. Nature Medicine 2018, 24: 535-537. PMID: 29736021, DOI: 10.1038/s41591-018-0033-7.Peer-Reviewed Original Research
2016
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.Peer-Reviewed Original ResearchConceptsMalignant mesotheliomaOverall survivalHigh mobility group box 1Mobility group box 1Development of MMIncidence of MMGroup box 1Novel therapeutic approachesNational Cancer InstitutePublic health authoritiesU.S. National Cancer InstitutePreventable malignancyStandard chemotherapyCancer CenterBlood biomarkersLung cancerMineral fibersClinical trialsCurrent treatmentOccupational exposureProtein 1 mutationConsensus reportTherapeutic approachesGermline BRCA1Clinical Oncology
2002
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw P, McLaughlin J, Zweemer R, Narod S, Risch H, Verheijen R, Ryan A, Menko F, Kenemans P, Jacobs I. Histopathologic Features of Genetically Determined Ovarian Cancer. International Journal Of Gynecological Pathology 2002, 21: 407-411. PMID: 12352190, DOI: 10.1097/00004347-200210000-00011.Peer-Reviewed Original ResearchConceptsInvasive serous carcinomasOvarian carcinomaSilverberg gradeGermline mutationsHistologic typeSerous carcinomaNuclear gradeGOG grade 3High histologic gradeBRCA1/BRCA2Serous histologyGynecologic pathologistsHistologic featuresHistopathologic featuresBRCA carriersHistologic gradeBRCA mutationsOvarian cancerArchitectural gradeBRCA2 mutationsGrade 3Germline BRCA1CarcinomaMutation statusControl group
1999
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer R, Shaw P, Verheijen R, Ryan A, Berchuck A, Ponder B, Risch H, McLaughlin J, Narod S, Menko F, Kenemans P, Jacobs I. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. Journal Of Clinical Pathology 1999, 52: 372. PMID: 10560359, PMCID: PMC1023075, DOI: 10.1136/jcp.52.5.372.Peer-Reviewed Original ResearchConceptsOvarian cancer casesBRCA2 germline mutationsHereditary ovarian cancerOvarian cancerCancer casesP53 accumulationGermline mutationsSomatic genetic eventsInvasive ovarian cancer casesBRCA2 germline mutation carriersOvarian cancer patientsP53 proteinGermline mutation carriersGenetic eventsRole of p53Cancer patientsAntigen retrieval techniqueBRCA mutationsBRCA2 mutationsStudy groupMutation carriersP53 alterationsP53 immunohistochemistryGermline BRCA1Positive cases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply